Imatinib Powder 152459-95-5

Product Details

Imatinib powder 152459-95-5 is an oral drug for the treatment of adult patients with Philadelphia chromosome (Ber-Abl)-positive chronic myeloid leukemia (CML) in blast phase, accelerated phase and chronic phase after failure of interferon therapy. CML is a hematopoietic stem cell disease caused by DNA abnormalities in stem cells in the bone marrow.

Imatinib powder 152459-95-5 was approved for marketing in the United States in May 2001 for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in blast phase, accelerated phase, or chronic phase patients after failure of alpha interferon therapy. Its revolutionary therapeutic effect on chronic myeloid leukemia can make the 10-year survival rate of chronic myeloid leukemia patients reach 85% to 90%, while before imatinib, the average survival time of patients was only 3-6. years, greatly extending the life cycle of patients.

The efficacy of imatinib mesylate in the treatment of gastrointestinal stromal tumors and chronic myeloid leukemia has been recognized, but its toxic and side effects are mainly seen in premarket clinical studies. The influencing factors, duration and related treatment of the drug’s toxic and side effects are rarely reported.

Health Benefits

• Treat Philadelphia chromosome (Ber-Abl)-positive chronic myeloid leukemia (CML) in blast phase;
• Imatinib is also effective in the treatment of gastrointestinal stromal tumors, with an effective rate of about 50%.